



Jazz Pharmaceuticals Announces Participation At The 2012 Morgan Stanley Global Healthcare Conference In New York On September 11

September 6, 2012

DUBLIN, Sept. 6, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will participate at the 2012 Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 11, 2012 at 9:45 a.m. EST / 2:45 p.m. GMT. Kate Falberg, executive vice president and chief financial officer, will provide a business update during a question and answer session with an analyst.

A live webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archived version of webcast will be available for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain, psychiatry and women's health. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate), Erwinaze™ (asparaginase *Erwinia chrysanthemi*), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by an international division, EUSA Pharma.

SOURCE Jazz Pharmaceuticals plc

William Craumer, Director, Investor Relations, Jazz Pharmaceuticals, Ireland + 353 1 634 3211, U.S. + 1-650-496-2750